The difference is that with SRX, the trials were an attempt to...

The difference is that with SRX, the trials were an attempt to expand the market and get it used as an earlier form of cancer treatment rather than just as a last resort salvage treatment.

Even though the trials failed, they still had a profitable growing market. AXP on the other hand is making no profits, sales are flat when they should be growing rapidly and not only is there clearly insufficient cash to get it to breakeven, there is the debt hanging over it. With the CEO unceremoniously booted, the board are obviously unhappy with the existing strategy given the lack of results.

However, with a decent capital injection, leadership and strategy, there could be a lot of money to be made in this. The big danger is dilution. Just hope whatever funding they get, retail holders get a look in so they aren't diluted into oblivion at these prices.

I don't think this will go to zero. Some other company will pick this up for a song before that happens. I can't imagine a breast implant manufacturer not picking this up given the prices AXP is trading at now.